SIGA Technologies | Q2 2024 Research Report

Things You Need to Know

Strong Financial Performance: SIGA Technologies has demonstrated robust financial health, with a 78% gross margin, consistent free cash flow, and a substantial revenue boost in Q2 2024.
SIGA’s flagship product, TPOXX, is a market leader in the smallpox antiviral space, approved in over 25 countries, with growing opportunities in response to global health threats like mpox.
While the company is expanding internationally, its heavy reliance on U.S. government contracts and the finite market for smallpox treatments poses a risk.

SIGA Technologies *One-Year Performance (08/26/2023 to 08/26/2024)*

Thesis

SIGA Technologies stands out as an investment opportunity due to its leadership in the smallpox antiviral market, driven by its flagship product, TPOXX. With FDA approval and distribution in over 25 countries, the company enjoys strong financial metrics, including a 78% gross margin and consistent free cash flow generation. This is bolstered by substantial government contracts, particularly in the U.S., providing a reliable revenue stream.

However, SIGA faces risks, primarily its heavy reliance on government contracts and the finite demand for smallpox vaccines, which limits growth potential within individual markets. While the company’s international expansion efforts are promising, future growth will depend on diversifying its product portfolio and reducing dependency on large, periodic government orders. This strategic pivot is crucial for sustaining long-term success and mitigating the impact of fluctuating revenues, which have historically resulted from the lump-sum payment structure of its contracts. As SIGA explores new markets and indications for TPOXX, it must balance its strong current financial position with the need for strategic innovation to ensure continued growth and resilience in a highly specialized market.

Business Catalysts

Market-Leading Product: SIGA’s TPOXX drug stands out for its superior efficacy, versatility, and safety, giving it a significant competitive edge. This advantage is reflected in its comparatively high operating margins.
Strong Financial Health: SIGA benefits from consistent cash flows, a solid cash reserve, and minimal debt, positioning the company well to enhance its offerings and navigate economic uncertainties.
Growing Mpox Threat: With the WHO declaring mpox a global health emergency, SIGA’s potential treatment could be highly lucrative if successfully brought to market.

Financial Overview

SIGA Technologies had a strong second quarter in 2024, with product sales surging to $21 million, driven by significant IV TPOXX sales to the U.S. Government. Total revenues for the quarter reached $21.8 million, a substantial increase from the previous year, while operating income and net income improved, signaling a turnaround from previous losses. The company secured a major $113 million procurement order in July and continues to expand its international presence, bolstering its revenue base and financial stability.

Financially, SIGA’s performance reflects its successful strategy of diversifying revenue streams and capitalizing on government contracts, particularly with the U.S. The significant increase in sales and profitability highlights the effectiveness of SIGA’s approach, especially with the growing demand for its TPOXX product. The recent developments in securing international orders and expanding its market reach further position the company for sustained growth, although it remains heavily reliant on U.S. government contracts.

Points of Criticism

New Leadership, Limited Investment: SIGA’s CEO and CMO, who joined within the last year, have minimal personal investment. While not critical, this raises concerns about whether their priorities align fully with shareholder interests.
US-Market Dependency: SIGA’s reliance on the U.S., which accounted for 79% of its revenue from 2020-2023, poses a risk. Any reduction in U.S. spending could significantly impact the company’s financial health.
Restricted Market Demand: Government demand for TPOXX is capped within specific periods, limiting potential growth. SIGA must diversify its drug pipeline to create more sustainable revenue streams.

Notable Updates in Q2 2024

08/21/2024: SIGA Technologies announced a new $9 million contract with the U.S. Department of Defense for the procurement of TPOXX®, marking their third such contract in three years. The company continues its partnership with the DOD to develop the Post-exposure Prophylaxis (PEP) indication for TPOXX®, supported by a $27 million development contract.
08/15/2024: The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) announced that SIGA’s PALM 007 trial for tecovirimat in treating monkeypox did not meet its primary endpoint of improving lesion resolution within 28 days, though meaningful improvements were observed in patients with severe disease or early treatment. The study confirmed tecovirimat’s safety and supported further trials to assess its benefits, particularly in severe cases or those treated early.
07/19/2024: SIGA Technologies announced that the U.S. Department of Health and Human Services exercised a $113 million procurement option for oral TPOXX® treatment courses. This order enhances orthopoxvirus preparedness and aligns with SIGA’s commitment to global health security while delivering value to shareholders.
06/17/2024: SIGA Technologies announced an agreement to expand access to its antiviral TPOXX (tecovirimat) across the ASEAN member states, marking a significant step in regional preparedness for public health events. The contract, coordinated with SIGA’s partner Meridian Medical Technologies, reflects ASEAN’s commitment to strengthening health security against threats like Mpox.

Download

Disclosures

Analyst Certification

Each author of Maker Capital Research on this report certifies that (i) the recommendations and opinions expressed in this research accurately reflect the author’s personal, independent, and objective views about any and all of the designated securities discussed (ii) no part of the author’s compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in the research, (iii) to the best of the author’s knowledge, she/he is not in receipt of material non-public information about the issuer, (iv) the author does not own securities in the company under coverage, and (v) the author adheres to the CFA Institute guidelines for analyst independence.

About Maker Capital Research

At Maker Capital Research, we are an independent equity research firm dedicated to uncovering high-quality businesses with market caps below $1 billion. Our expert team employs a fundamental, long-term investment strategy that emphasizes business sustainability and predictability. By meticulously analyzing a company’s operations, competitive advantages, financials, and management team, we assess the true quality of potential investments. Our research serves discerning investors who value in-depth insights and seek to make well-informed investment decisions. At Maker Capital Research, we provide the crucial information that empowers investors to identify and invest in promising businesses.

General Information

Maker Capital Research Corporation (MCR), a subsidiary of Apollo Relations, has created and distributed this report. This report is based on information we consider reliable; we have not been provided with any material non-public information by the company (or companies) discussed in this report. We do not represent that this report is accurate or complete and it should not be relied upon as such; further, any information in this report is subject to change without any formal or type of notice provided. Investors should consider this report as only one factor in their investment decisions; this report is not intended as a replacement for an investor’s independent judgment.

Apollo Relations is not an IIROC registered dealer and does not offer investment banking services to its clients. Apollo Relations (and its employees) do not own or have a beneficial interest in the securities of the company being provided research services and do not own a majority or special interest in the business. Apollo Relations does not serve as an officer or Director of the company discussed in this report. Apollo Relations does not make a market in any securities. This report is not disseminated in connection with any distribution of securities and is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal.

Apollo Relations does not make any warranties, expressed or implied, as to the results to be obtained from using this information and makes no express or implied warranties for particular use. Anyone using this report assumes full responsibility for whatever results they obtain. This does not constitute a personal recommendation or take into account any financial or investment objectives, financial situations, or needs of individuals. This report has not been prepared for any particular individual or institution. Recipients should consider whether any information in this report is suitable for their particular circumstances and should seek professional advice. Past performance is not a guide for future results, future returns are not guaranteed, and loss of original capital may occur. Neither Apollo Relations nor any person employed by Apollo Relations accepts any liability whatsoever for any direct or indirect loss resulting from any use of its research or the information it contains.

This report contains “forward-looking” statements. Forward-looking statements regarding the Company and/or stock’s performance inherently involve risks and uncertainties that could cause actual results to differ from such forward-looking statements. Such statements involve a number of risks and uncertainties such as competition, technology shifts, market demand, and the company’s (and management’s) ability to correctly forecast financial estimates; please see the company’s MD&A “Risk Factors” Section for a more complete discussion of company-specific risks for the company discussed in this report.

Apollo Relations retains full editorial control over its research content. Apollo Relations does not have investment banking relationships and does not expect to receive any investment banking-driven income. Apollo Relations reports are primarily disseminated electronically and, in some cases, in printed form. Electronic reports are simultaneously available to all recipients in any form. Reprints of Apollo Relations reports are prohibited without permission. To receive future reports on covered companies please visit https://www.makercapitalresearch.com/research or subscribe to our website.
The information contained in this report is intended to be viewed only in jurisdictions where it may be legally viewed and is not intended for use by any person or entity in any jurisdiction where such use would be contrary to local regulations or which would require any registration requirement within such jurisdiction.